Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

Study of GS-0151 in Participants With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT06902519

Public ClinicalTrials.gov record NCT06902519. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Randomized, Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of GS-0151 in Adult Participants With Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.

Study identification

NCT ID
NCT06902519
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
65 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 13, 2025
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027
Last update posted
Sep 2, 2026

2025 – 2027

United States locations

U.S. sites
18
U.S. states
9
U.S. cities
18
Facility City State ZIP Site status
Pinnacle Research Group, LLC Anniston Alabama 36207
University of California, San Diego La Jolla California 92037
Stanford University School of Medicine Palo Alto California 94304
Medvin Clinical Research Tujunga California 91042
Medvin Clinical Research Whittier California 90602
Clinical Research of West Florida, Inc Clearwater Florida 33765
Great Lakes Clinical Trials dba Flourish Research Chicago Chicago Illinois 60640
Accurate Clinical Research, Inc Lake Charles Louisiana 70605
Lynn Health Science Institute Oklahoma City Oklahoma 73112
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
Accurate Clinical Management, LLC Baytown Texas 77521
Precision Comprehensive Clinical Research Solutions Colleyville Texas 76034
Accurate Clinical Research, Inc Houston Texas 77089
Precision Comprehensive Clinical Research Solutions Irving Texas 75061
Southwest Rheumatology Research Mesquite Texas 75150
Clinical Trials of Texas LLC, dba Flourish Research San Antonio Texas 78229
DM Clinical Research Tomball Texas 77375
Tidewater Clinical Research, LLC/ Virginia Rheumatology Clinic Virginia Beach Virginia 23456

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06902519, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06902519 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →